These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16280694)

  • 1. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
    AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
    Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
    Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
    Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M
    Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
    Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
    Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
    Clotet B; Capetti A; Soto-Ramirez LE; Gatell JM; Rowell L; Salgo M; Schapiro JM
    J Antimicrob Chemother; 2008 Dec; 62(6):1374-8. PubMed ID: 18782780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
    Hardy H; Skolnik PR
    Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
    Viard JP; Fagard C; Chaix ML; Rouzioux C; Bouteloup V; Bentata M; de Verdière NC; Pahlavan G; Weiss L; Lévy Y; Chêne G;
    AIDS; 2009 Jul; 23(11):1383-8. PubMed ID: 19461505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J
    J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.